Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Sitagliptin in T2D (SUSTAIN China)
NCT03061214Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2017
- Primary completion
- Mar 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c at 30 weeks. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03061214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061214.